stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Return on equity
Xencor, Inc.'s return on equity over the twelve months to 30 June 2026 was −29.1%, down 15.0 percentage points from fiscal 2025 (−14.0%). Over the past ten years it has ranged from −34.8% (fiscal 2024) to 18.9% (fiscal 2016); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −14.0% | 20.78 |
| FY2024 | −34.8% | (15.66) |
| FY2023 | −19.2% | (11.61) |
| FY2022 | −7.55% | (20.20) |
| FY2021 | 12.7% | 24.55 |
| FY2020 | −11.9% | (16.72) |
| FY2019 | 4.82% | 21.62 |
| FY2018 | −16.8% | (4.59) |
| FY2017 | −12.2% | (31.15) |
| FY2016 | 18.9% | 34.81 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ADMA ADMA Biologics Inc compare | 42.0% |
| BEAM Beam Therapeutics Inc. compare | −11.3% |
| XNCR Xencor, Inc. | −29.1% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −30.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| MBX MBX Biosciences, Inc. compare | −33.2% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| PHVS Pharvaris N.V. compare | −71.5% |
| RCUS Arcus Biosciences, Inc. compare | −114.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement